ACADIA Pharmaceuticals Inc. Can’t Be More Risky. Option Traders Sell It

 ACADIA Pharmaceuticals Inc. Can't Be More Risky. Option Traders Sell It

In today’s session ACADIA Pharmaceuticals Inc. (ACAD) recorded an unusually high (776) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the December, 2016 put, expecting serious ACAD decrease. With 776 contracts traded and 14974 open interest for the Dec, 16 contract, it seems this is a quite bearish bet. The option with symbol: ACAD161216P00026000 closed last at: $2.5 or 4.2% up. About 828,197 shares traded hands. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has declined 12.52% since April 13, 2016 and is downtrending. It has underperformed by 16.45% the S&P500.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Ratings Coverage

Out of 7 analysts covering ACADIA Pharmaceuticals (NASDAQ:ACAD), 4 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 57% are positive. ACADIA Pharmaceuticals has been the topic of 16 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has “Overweight” rating given on Friday, August 7 by Piper Jaffray. On Tuesday, October 4 the stock rating was initiated by Leerink Swann with “Mkt Perform”. The rating was maintained by Cowen & Co with “Outperform” on Sunday, August 9. The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has “Buy” rating given on Tuesday, November 8 by Bank of America. The rating was reinitiated by Roth Capital with “Neutral” on Wednesday, October 19. The firm earned “Buy” rating on Friday, August 7 by Needham. The firm earned “Neutral” rating on Thursday, August 27 by Piper Jaffray. Piper Jaffray downgraded ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) on Friday, August 7 to “Neutral” rating. The rating was upgraded by Piper Jaffray on Friday, January 22 to “Overweight”. The rating was maintained by JP Morgan on Friday, September 4 with “Buy”.

According to Zacks Investment Research, “Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson’s disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia.”

Insitutional Activity: The institutional sentiment decreased to 1.02 in Q2 2016. Its down 0.31, from 1.33 in 2016Q1. The ratio dropped, as 32 funds sold all ACADIA Pharmaceuticals Inc. shares owned while 68 reduced positions. 41 funds bought stakes while 61 increased positions. They now own 104.57 million shares or 4.71% less from 109.74 million shares in 2016Q1.
Senator Inv Gp Ltd Partnership accumulated 0.42% or 800,000 shares. The New Jersey-based Palisade Mgmt Limited Liability Com Nj has invested 0.08% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). North Star Investment holds 0.01% of its portfolio in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 880 shares. Clearbridge Invests Lc holds 0% of its portfolio in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 500 shares. Tower Research (Trc) owns 4,205 shares or 0.01% of their US portfolio. Mycio Wealth Ltd Liability Corp last reported 0% of its portfolio in the stock. Omers Administration Corporation holds 0.01% of its portfolio in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 7,600 shares. Franklin, a California-based fund reported 3.37 million shares. X Management Limited Liability Company owns 244 shares or 0% of their US portfolio. Dekabank Deutsche Girozentrale accumulated 0.04% or 97,100 shares. Glg Lc holds 20,000 shares or 0.05% of its portfolio. Pnc Fincl Svcs Group Incorporated Inc last reported 0% of its portfolio in the stock. Tci Wealth has invested 0.02% of its portfolio in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Metropolitan Life Insurance Ny holds 0% or 6,799 shares in its portfolio. Sandy Spring National Bank has 1,500 shares for 0.01% of their US portfolio.

Insider Transactions: Since July 11, 2016, the stock had 2 buys, and 2 selling transactions for $42.17 million net activity. HARRIGAN EDMUND also bought $32,970 worth of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares. On Wednesday, August 10 the insider BAKER BROS. ADVISORS LP bought $43.00 million. Baity Glenn also sold $306,687 worth of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) on Thursday, November 10.

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The company has a market cap of $3.45 billion. The Firm is focused on the development and commercialization of medicines for central nervous system disorders. It currently has negative earnings. The Company’s lead drug candidate, NUPLAZID , is under development for the treatment of Parkinson’s disease psychosis (PDP).

ACAD Company Profile

ACADIA Pharmaceuticals Inc., incorporated on January 16, 1997, is a biopharmaceutical company. The Firm is focused on the development and commercialization of medicines for central nervous system disorders. The Company’s lead drug candidate, NUPLAZID (pimavanserin), is under development for the treatment of Parkinson’s disease psychosis (PDP).

More news for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) were recently published by: Nasdaq.com, which released: “Earnings Reaction History: ACADIA Pharmaceuticals Inc, 42.9% Follow-Through …” on November 07, 2016. Seekingalpha.com‘s article titled: “ACADIA Pharmaceuticals Is Looking Increasingly Attractive” and published on October 26, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment